
# Left main bifurcation PCI: Similarity and difference between DKCRUSH-V vs. EBC Main


Shao-Liang Chen, MD
Nanjing First Hospital
Nanjing Medical University
China

I, Dr. Shao-Liang Chen, have nothing to disclose

## Objectives of clinical trials



#### Objectives of clinical trials



## Study inclusion criteria

	EBC Main	DKCRUSH V	
Sample size	Estimated 450, Finally 467	Estimated 484; finally 482	
SYNTAX scores	<32 scores	No limit	
AMI	>72 h	>24 h	
СТО	Excluded	Included after opened	
Two-stent	T/TAP, culotte, or DK crush	DK crush	
Exact two-stent	Culotte: 53%; TAP: 33% DK crush:5%	DK crush: 100%	
Primary endpoint at 1-year	Death, MI, TLR; Superiority design	Cardiac death, TVMI, TLR; Superiority design	

EBC MAIN, Eur Heart J 2021; DKCRUSH V, JACC 2017

#### Assumption and lesions specificities

	EBC Main	DKCRUSH V	
Primary endpoint	25% in two-stent group	14% in provisional group	
at 1-year	14% in provisional group	7% in DK crush group	
SYNTAX scores	23 scores	31 scores	
No.PCI yearly/PI	>150/per operator	>300/per operator, ≥20 LM-PCI	
SB lesion length	7 mm	16 mm	
Lesion types	Medina 111/011	Medina 111/011	
Complexity	Not classified	Complex bifurcations in 31.5%	


<sup>✓</sup> SCAI definition of PMI was used in EBC MAIN, but CK-MB increase >5-10 times was applied in the DKCRUSH V study


#### **Procedures and outcome**

		EBC Main		DKCRUSH V	
Cross-over to 2-stent		22%		41%	
Reasons for treating SB		TIMI<3, >A dissection, >90% compromise		TIMI <3, >A dissection, >75% compromise	
IVUS use		40%		41%	
Endpoints		Provisional	Two-stent	Provisional	DK crush
Primary		14.7%	17.7%	10.7%	5.0%
Secondary	Death	3%	4.2%	CD: 2.1%	1.2%
	MI	10%	10.1%	TVMI:2.9%	0.4%
	TLR	6.1%	9.3%	7.9%	3.8%
	ST	1.7%	1.3%	3.3%	0.4%


EBC MAIN, Eur Heart J 2021; DKCRUSH V, JACC 2017


#### Landmark analysis of DKCRUSH V trial






#### Landmark analysis of DKCRUSH V trial






#### Landmark analysis of DKCRUSH V trial




#### 3-year clinical results




DKCRUSH V, JACC: CVINT 2018

#### Stratified by lesion's complexity—DEFINITION criteria




Simple lesions




**Complex lesions** 

DKCRUSH V, JACC: CVINT 2018

#### Similarity between EBC Main and DKCRUSH V





DKCRUSH V, JACC 2017

# Thanks for your attention!